ICU: the cashflow

MyFinsight

The latest financial statement is for the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net income (loss) attributable to parent	-9,246	-
Amortization of deferred financing costs	18	-
Change in fair value of convertible notes (issued, converted and outstanding)	0	-
Change in fair value of liability classified warrants (exercised and outstanding)	0	-32
Shares issued for the standby equity purchase agreement commitment fee	298	-
Stock-based compensation	290	264
Change in fair value of convertible notes (issued, converted and outstanding)	-	0
Accounts receivables, net	4	105
Net loss	-	-5,774
Inventory	6	77
Prepaid expenses	-244	-784
Other assets	-80	-156
Accounts payable	-1,140	112
Shares issued for the standby equity purchase agreement commitment fee	-	298
Accrued expenses	164	-1,305
Amortization of deferred financing costs	-	18
Other liabilities	0	0
Net cash used in operating activities	-3,844	-5,661
Proceeds from issuance of convertible notes	0	0
Payment of convertible notes	0	0
Proceeds from exercise of warrants	-	2
Proceeds from issuance of shares, net of offering costs	9,183	5,154
Proceeds from exercise warrants-Convertible Note Warrants	1,818	-
Proceeds of pre-funded warrants	5,886	5,580
Payment of notes payable	0	592
Net cash provided by financing activities	11,305	10,144
Net increase in cash	11,944	-
Cash and cash equivalents at beginning of period	1,819	-
Net increase in cash	-	4,483
Cash and cash equivalents at end of period	13,763	-

Unit: Thousand (K) dollars